Company profile: AiCuris
1.1 - Company Overview
Company description
- Provider of resistance breaking antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, hepatitis B and C, and multi-resistant bacteria; offerings include PREVYMIS for CMV prevention in adult CMV-seropositive allogeneic stem cell or kidney transplant recipients, pritelivir (phase 3) for acyclovir-resistant HSV, AIC468 (preclinical) for BK virus, adenovirus treatment programs, and the AiCubator for early-stage research on viral infections in immunocompromised patients.
Products and services
- AIC468: Antisense oligonucleotide designed to prevent BK virus infections and reactivation in kidney transplant patients, currently in preclinical development
- PREVYMIS®: Commercialized antiviral product that prevents cytomegalovirus infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell or kidney transplants
- Pritelivir: Phase 3 therapeutic candidate treating acyclovir-resistant herpes simplex virus infections in immunocompromised patients, specifically targeting drug-resistant HSV.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AiCuris
Artus Biotech
HQ: Germany
Website
- Description: Provider of DNA-based diagnostic kits focused on PCR and real-time PCR, developed, produced, and sold for detection of infectious agents and use in pharmacogenomics and veterinary applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artus Biotech company profile →
Mpex Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development of new therapies to combat antibiotic resistance, with a particular focus on gram-negative organisms. The company's internal pipeline combines proprietary formulations, PK/PD strategies and novel potentiating agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mpex Pharma company profile →
Bioquell
HQ: United Kingdom
Website
- Description: Provider of biodecontamination systems and services specializing in Hydrogen Peroxide Vapor technology to eliminate bacteria, viruses, fungi, and spores. Products include Bioquell Hydrogen Peroxide Vapour Decontamination (35% H2O2 vapor for surface and airborne pathogen elimination), Rapid Bio-Decontamination Service, ProteQ automated room decontamination, and Qube isolators for sterility testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioquell company profile →
Oxsed
HQ: United Kingdom
Website
- Description: Provider of accurate and rapid testing worldwide to minimize the impact of disease on individuals and communities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxsed company profile →
Alphyn Biologics
HQ: United States
Website
- Description: Provider of proprietary drug therapies for skin diseases, including Zabalafin hydrogel (AB-101a), a steroid-free topical for atopic dermatitis targeting immune and bacterial components; the Zabalafin (AB-101) multi-bioactive platform; and AB-101b in development for Epidermolysis Bullosa to address inflammation, itch, pain, and skin infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alphyn Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AiCuris
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AiCuris
2.2 - Growth funds investing in similar companies to AiCuris
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AiCuris
4.2 - Public trading comparable groups for AiCuris
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →